ImmunoGen saw the highest growth of 112% in patent filings in November and 224% in grants in December in Q4 2023. Compared to Q3 2023, Q4 2023 saw an increase in patent filings by 88% and grants by 59%. GlobalData’s DataBook provides a comprehensive analysis of ImmunoGen‘s patent filings and grants. Buy the databook here.
ImmunoGen has been focused on protecting inventions in United States(US) with ten publications in Q4 2023
The United States(US) Patent Office dominates the patent filings and grants with nearly 86% filings and 100% grants. The United States(US), and European Patent Office(EPO) patent Office are among the top ten patent offices where ImmunoGen is filings its patents. Among the top granted patent authorities, ImmunoGen has 100% of its grants in United States(US)
Manufacturing/industrial related patents lead ImmunoGen portfolio followed by ovarian cancer, and lung cancer
ImmunoGen has highest number of patents in manufacturing/industrial followed by ovarian cancer, lung cancer, petrochemicals, and peritoneal cancer. For manufacturing/industrial, nearly 33% of patents were filed and 7% of patents were granted in Q4 2023.
For comprehensive analysis of ImmunoGen's filings and grants, buy the databook here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.